Clinical Trials & Latest Studies Lead To Developments Indicating Cannabinoids

223Today’s leading companies with recent developments of interest are Cannabis Science, Inc. (OTC: CBIS), Compass Diversified Holdings (NYSE: CODI ), NEMUS Bioscience, Inc. (OTC: NMUS), GW Pharmaceuticals (NASDAQ: GWPH ) and Insys Therapeutics, Inc. (NASDAQ: INSY ) Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announced that it has entered into a comprehensive clinical drug development to focus on delivering GMP quality pre-clinical data to enable entry of CS-NEURO-1 into a Phase I human study in Europe with ImmunoClin (OTC: IMCL).

After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science.

To read more, visit–conditions-562628081.html

Posted in: Investing

Comments are closed.